Linked Data API

Show Search Form

Search Results

1123746
star this property human indexable true more like this
star this property published true more like this
star this property registered interest false remove filter
star this property answer date less than 2019-05-14more like thismore than 2019-05-14
star this property date less than 2019-04-29more like thisremove minimum value filter
star this property date tabled less than 2019-04-29more like thismore than 2019-04-29
star this property ddp created less than 2019-04-29T20:35:22.247Zmore like thismore than 2019-04-29T20:35:22.247Z
star this property answering body
Department of Health and Social Care more like this
star this property question status Tabled more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property ddp modified
less than 2019-04-29T20:45:45.988Zmore like thismore than 2019-04-29T20:45:45.988Z
less than 2019-05-14T17:01:02.470Zmore like thismore than 2019-05-14T17:01:02.470Z
star this property hansard heading Antibiotics: Drug Resistance more like this
unstar this property house id 2 more like this
star this property identifier HL15384 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property parliament number 57 more like this
star this property question first answered
less than 2019-05-14T16:29:42.253Zmore like thismore than 2019-05-14T16:29:42.253Z
star this property question text To ask Her Majesty's Government what assessment they have made of the effectiveness of their 2013–18 antimicrobial resistance strategy at addressing the problem of multi-resistant E. coli-like bacteria; what assessment they have made of recent trends in the number of multi-resistant E. coli-like bacteria in the UK; and what factors inform their view of the balance between efforts to reduce transmission and efforts to reduce the use of antibiotics. more like this
star this property session
2017/19 more like this
star this property session number 1 more like this
star this property tabling member printed
Baroness Gardner of Parkes more like this
star this property title House of Lords Tabled Parliamentary Question 2017/19 HL15384 more like this
star this property type
WrittenParliamentaryQuestion
star this property uin HL15384 remove filter
star this property version 1 more like this
star this property written parliamentary question type Ordinary more like this
star this property answer
answer
unstar this property answer text <p>While we can count many successes from our 2013-18 Antimicrobial Resistance (AMR) Strategy, resistance has continued to increase. In the United Kingdom we have seen a 35% increase in resistant blood stream infections in humans from 2013-17.</p><p>The number of bloodstream infections (BSIs) is increasing each year. Although the proportion of antibiotic resistant BSIs remain stable year to year, the burden on resistance increases. This is mostly due to increasing prevalence of E.coli bloodstream infections.</p><p>Estimates of the multi-resistant cases can be made, however not all the bacteria are tested against the same antibiotics, so a definitive number of cases cannot be given. The Public Health England Fingertips tool also has an indicator showing the rolling quarterly average proportion of E. coli blood specimens non-susceptible to at least three of the key antimicrobials (gentamicin, ciprofloxacin, piperacillin/tazobactam, 3rd-generation cephalosporins or carbapenems). For England this is 5.5% with little fluctuation over time.</p><p>This is exactly why the UK’s five-year national action plan for AMR, published alongside the UK 20-year vision for AMR on 24 January 2019, includes a strengthened focus on infection prevention and control, renewing our commitment to halve levels of healthcare associated Gram-negative blood stream infections (mostly E.coli) by 2023-24. The plan also sets a world-first target to reduce the actual numbers of resistant infections, with the aim to reduce them by 10% by 2025.</p><p>We are working with the devolved health administrations to develop consistent methodologies for reporting the incidence and mortality of key antibiotic resistant infections and antimicrobial use to allow us to report progress on the ambitions of the AMR national action plan.</p><p>As reductions in inappropriate prescribing also reduces the risk of promoting the growth of antibiotic-resistant bacteria, interventions to reduce antibiotic prescribing or transmission of the bacteria are complementary.</p><p> </p>
star this property creator
3596
star this property label Biography information for Baroness Gardner of Parkes more like this
star this property publisher
25277
star this property pref label House of Lords more like this
star this property tabling member
3596
unstar this property label Biography information for Baroness Gardner of Parkes remove filter